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iting in recent years. This technique allows for gene knockout
and evaluation of function in cell lines in a manner that is far
easier and more accessible than anything previously available.
Unfortunately, the ability to extend these studies to in vivo syn-
geneic murine cell line implantation is limited by an immune
response against cells transduced to stably express Cas9. In
this study, we demonstrate that a non-integrating lentiviral
vector approach can overcome this immune rejection and allow
for the growth of transduced cells in an immunocompetent
host. This technique enables the establishment of a von
Hippel-Lindau (VHL) gene knockout RENCA cell line in
BALB/c mice, generating an improved model of immunocom-
petent, metastatic renal cell carcinoma (RCC).Received 30 September 2017; accepted 20 February 2018;
https://doi.org/10.1016/j.omtm.2018.02.009.
10These authors contributed equally to this work.
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Murine models have proved an invaluable tool in studying the molec-
ular contributors to the development and progression of cancer.1 The
discovery and utilization of novel genetic tools, such as homologous
recombination and small hairpin RNA (shRNA) gene knockdown,
have led to a myriad of important discoveries in this field.2 Now
the new CRISPR technique is poised to continue in this vein with
its own revolution.2 Already this technique has been leveraged in a va-
riety of studies that have led to interesting findings regarding tumor
development, metastasis, and treatment susceptibility.3–5 However,
there is an absence of reports of using this technology to produce
in vitro gene changes in murine cell lines that can then be implanted
into immunocompetent hosts in novel murine models. Perhaps the
reason for this absence is due to an immune reaction against the bac-
terial Cas9 protein, as has been previously demonstrated.6
In contrast to many human cell lines, some murine cell lines are not
amenable to highly efficient transfection.7,8 For this reason, a lentiviral
approach has been commonly used to modify these cells in vitro.9–11Molecular Therapy: Methods
This is an open access article under the CC BY-NC-Transduction by lentivirus leads to highly effective gene expression
but involves stable integration of the introduced exogenous genes,
allowing for a potential immune rejection.12 Studies have shown
that integrase-defective lentiviral vectors are capable of producing
nonintegrated viral DNA transiently that can support transcription.13
In this study, we produced CRISPR-modified murine cell lines using
engineered non-integrating lentiviral (NIL) vectors containing
mutated integrase developed by Nightingale et al.14 We go on to
show that the murine renal cell carcinoma RENCA cell line produced
by the NIL CRISPR vectors grows just as well in the syngeneic BALB/c
mice as the wild-type parental cell line, whereas the cell line with stable
viral integration either fails to grow or eventually regresses. To date,
there is no syngeneic mouse model of metastatic renal cell carcinoma
(RCC) that is deficient in the von Hippel-Lindau (VHL) tumor sup-
pressor gene, yet 80%–90% of patients with clear cell RCC, the most
common type of RCC accounting for nearly all metastatic cases,
have a defect in the VHL pathway.15 Thus, a model that is both im-
mune competent andVHL deficient would greatly improve our ability
to perform relevant preclinical studies in RCC. Using this NIL tech-
nique, we were able to generate a novel, immunocompetent murine
model of metastatic RCC by CRISPR-mediated knockout of VHL.RESULTS
Using NIL to Generate Clonal Cas9-Modified Cell Lines
In a recent study, we employed the lentiviral CRISPR-Cas9 method to
perform gene editing in several RCC cell lines in an effort to dissect& Clinical Development Vol. 9 June 2018 ª 2018 The Authors. 203
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Generation of Cas9-Transduced, Non-
integrating Cells
(A) Schematic representation of lentiCRISPR with gRNA
targeting murine VHL downstream of a U6 promoter. Cells
were derived by infection with this lentivirus packaged with
either wild-type or mutated integrase. Other elements of
the virus include tandem long terminal repeat sequences
(LTR), Psi signal, central polypurine tract (cPPT), EFS
promoter, Cas9 sequence, P2A element, puromycin
resistance gene (Puro), and WPRE. (B) Cas9 gene
expression in RC clonal lines were assessed by RT-PCR.
The expression of NIL-generated clones RC(NIC1),
RC(NIC2), and RC(NIC3) relative to the integrated
lentiCRISPR-generated line, RC1, is shown. The Cas9
expression in RC1 is normalized to 1. (C) Western blot for
Cas9 in RENCA, RC1, and RC(NIC1) cells. Cas9 protein is
shown for positive control in the left lane. (D) Light micro-
scopic images of RC1 and RC(NIC1) cells at 10 magni-
fication. (E) qRT-PCR analysis of genes in RC1 and
RC(NIC1) cells.
Molecular Therapy: Methods & Clinical Developmentthe molecular pathways involved in the oncogenesis of this disease.15
Interestingly, we showed that knocking out the VHL tumor suppres-
sor gene in the RCC cell lines led to epithelial mesenchymal transition
(EMT) and increased metastasis in vivo, specifically in the murine
RENCA model. However, when we attempted to implant the
lentiCRISPR-modified RENCA cell lines into their syngeneic immu-
nocompetent BALB/c hosts, the tumors failed to grow.16 In multiple204 Molecular Therapy: Methods & Clinical Development Vol. 9 June 2018studies, we would observe initial tumor growth
in the first week followed by subsequent tumor
regression and complete disappearance by
4 weeks (data not shown). The initial VHL-null
RENCA cell line (RVN) and its control (RC, us-
ing irrelevant luciferase-targeted guide RNA)
generated with integrating Cas9 were mixed
cell populations produced after transduction
with high virus-to-cell ratio of the respective
lentiCRISPR. A schematic representation of the
lentiCRISPR vector is shown in Figure 1A. To
better pinpoint the problem of non-engraftment,
we selected individual clonal populations from
the initial lentiCRISPR-derived RC and RVN
mixed populations and designated them as
RC1 and RVN1. Attempts to engraft these clon-
ally selected lines into BALB/c mice also failed
(data not shown). Given reports of a cell-medi-
ated immune response to the Cas9 protein,6 we
thought it possible to avoid this immune-medi-
ated rejection through transducing the cells
with NIL.We generated the control lentiCRISPR
vectors using the packaging constructs with an
integrase mutation.14 Although the viral inte-
grase function is crippled, a low level of integra-
tion is still possible. For this reason, we screened
several of the clonally selected RC lines for thelowest Cas9 expression (Figure 1B). The NIL-transduced RC clonal
lines are designated as RC(NIC1), RC(NIC2), and RC(NIC3). Among
these three NIL-derived clone (NIC) lines, RC(NIC1) exhibited
lowest Cas9 expression at a level that is nearly three orders of magni-
tude lower than RC1. Western blot further confirmed Cas9 protein
expression is present in RC1, but not in the RC(NIC1) cell line (Fig-
ure 1C). Both RC1 and RC(NIC1) cells displayed the cobblestone
Figure 2. UsingNon-integrating Lentivirus Allows for
Growth of lentiCRISPR-Modified Cells in an
Immunocompetent BALB/c Host
(A) Growth curves for subcutaneous tumors implanted
with RENCA, RC(NIC1), and RC1 cells over 20 days in
BALB/c mice. n = 4 per group. (B) Images of gross tumors
from three representative animals in each group are
shown. The RC1 tumor in the fourth animal completely
regressed. (C) Representative H&E images of tumors from
each of three groups in both 4 and 20 magnification
are shown. (D) Representative images of immunohisto-
chemistry staining of CD3 in RC(NIC1) and RC1 tumors
(**p < 0.01).
www.moleculartherapy.orgepithelial morphology, with no discernable cell morphologic differ-
ences between them (Figure 1D). Furthermore, we analyzed the
mRNA level of several key genes, such as GLUT-1, E-cadherin,
N-cadherin, and integrins ITGAV, ITGB3, and ITGB5. There is no
significant difference in the expression of these genes in the two cell
lines (Figure 1E).
NIC Cells Grow in an Immunocompetent BALB/c Host
Next, we compared the ability of RC1 and RC(NIC1) with parental
RENCA cells to establish subcutaneous tumors in syngeneic BALB/c
mice. As expected, the implanted parental RENCA cells grewMolecular Therapy: Methodsrobustly, reaching tumor size of 1.5 cm in diam-
eter in about 3 weeks (Figure 2). In contrast, the
clonally selected RC1 cell line with stable Cas9
expression showed impaired initial growth fol-
lowed by regression (Figure 2A), as we have
observed in our previous studies. Interestingly,
the RC(NIC1) line grew at a rate comparable
to the parental RENCA line (Figure 2A). Gross
examination of harvested tumor revealed
healthy, well-vascularized tumors established
with the RENCA and RC(NIC1) cells. In
contrast, the three small RC1 tumors are
pale and fibrotic in appearance, and the tumor
in the fourth animal completely regressed
(Figure 2B).
An Immune Reaction Mediates Rejection of
Cas9-Expressing Cells
Further histological analyses revealed by H&E
staining showed RENCA and RC(NIC1) tumors
contain healthy mitotic tumor cells with large
nuclei (Figure 2C). In contrast, the residual
RC1 tumors contained large regions of non-
cellular matrix surrounding small cellular
islands. In one of the RC1 tumors with the
most abundant tumor cells, a prominent infiltra-
tion of immune cells and lymphocytes with
irregular-shaped or small dense nuclei can be
seen in the tumor (Figure 2C). Immunohisto-chemical staining with CD3 revealed a dramatically increased lym-
phocytic infiltration in the RC1 tumor that was absent in the
RC(NIC1) tumor (Figure 2D). To further support the presence of
an immune rejection against the RC1 tumors, we utilized an ELISA
to test for immunoglobulin G1 (IgG1) targeting Cas9. As suspected,
expression of Cas9-targeted IgG1 was elevated in serum from mice
harboring RC1 tumor, but not in RENCA or RC(NIC1) tumor
bearing mice (Figure S1). Interestingly, immunogenic response
against different foreign proteins in mice is not uniform. For instance,
no retardation of engraftment of RENCA-FL cells was observed in
BALB/c mice (Figure S2; see also Figure 4). This cell line was& Clinical Development Vol. 9 June 2018 205
Figure 3. Generation of Clonally Selected, Non-
integrating, VHL Knockout RENCA Cells
(A) Cas9 gene expression levels in seven clonal, non-
integrating RVN lines (RVN(NIC1–7)) were assessed by
RT-PCR. The expression level in an RC1 integrated
lentiCRISPR generated line is set at 1. (B) The DNA se-
quences in the mVHL coding region from RC(NIC1) and
RVN(NIC5) are shown with the reference sequence. A
10-base-pair deletion within the region targeted by our
VHL gRNA was found in RVN(NIC5) cells, but not in
RC(NIC1). Please note: from here on, the RC(NIC1) clonal
line will be designated as VHL-WT and the RVN(NIC5)
clonal line as VHL-KO. (C) Representative images of VHL-
WT and VHL-KO cells under light microscopy with 10
fields. (D) Cell proliferation assay and (E) western blot for
VHL, HIF-1a, E-cadherin, and b-actin in VHL-WT and
VHL-KO cells. Gene expression was assessed by RT-
PCR for (F) Glut-1, (G) E-cadherin, and (H) N-cadherin
(*p < 0.05, **p < 0.01, ***p < 0.001). (I) Either VHL-WT or
VHL-KO cells were implanted into the subcapsular space
of the left kidney in NU/J nude female 5-week-old mice.
VHL-WT tumors grew well, while VHL-KO tumors grew
poorly, as monitored by firefly-luciferase-based in vivo
bioluminescence imaging. No lung metastasis was seen
in both tumor groups.
Molecular Therapy: Methods & Clinical Developmentgenerated by transducing with a conventional integrating lentivirus
expressing firefly luciferase (FL). Taken all together, our findings
suggest that this immune-mediated rejection is likely directed at the
stably expressed Cas9 protein in our lentiCRISPR-modified RENCA
cell lines.
Using the NIL Approach to Generate a VHL Knockout
Immunocompetent Metastatic RCC Model
Because the transiently expressing NIL appeared to overcome the
immunogenicity against Cas9, we sought to verify whether the NIL
CRISPR vector could indeed achieve the designed targeted gene
disruption. We have recently reported the knockout of the VHL tu-
mor suppressor gene in the RENCA cell line by lentiCRISPR-pro-
moted EMT and dramatically increased metastatic behavior in vivo
in immunodeficient mice.15 We regenerated the VHL-knockout206 Molecular Therapy: Methods & Clinical Development Vol. 9 June 2018RENCA cell line with the NIL CRISPR vector
and clonally selected seven lines, designated as
RVN(NIC1) to RVN(NIC7). The level of Cas9
expression was assessed in these clonal lines
(Figure 3A). We selected the RVN(NIC5) line
for further analyses based on its very low
level of Cas9 expression, which is less
than 0.0001 of the integrating lentiCRISPR-
generated RVN1. DNA sequencing revealed a
10-base-pair deletion within the region targeted
by our guide RNA (gRNA) in RVN(NIC5) (Fig-
ure 3B). Please note: since we have selected the
optimal NIC line to study further on, we will
refer to the RENCA control, RC(NIC1) clonalline as VHL-WT and the RVN(NIC5) clonal line as VHL-KO. This
will simplify the nomenclature with the genomic designation of
each line.
Next, we analyzed the functional consequences of the VHL gene dele-
tion. The VHL-KO line displayed a mesenchymal cell morphology,
while the appearance of VHL-WT control line is consistent with an
epithelial morphology (Figure 3C). The in vitro growth rate of
VHL-KO line was significantly lower than VHL-WT (Figure 3D).
Western blot showed loss of VHL expression, HIF-1a upregulation
and E-cadherin downregulation in the VHL-KO cells (Figure 3E).
Expression analyses for Glut-1, E-cadherin and N-cadherin were
also consistent with expectations for the loss of VHL gene (Figures
3F–3H). These EMT changes in vitro are the same as we have reported
for the non-clonal RVN line.15 These findings further support that the
www.moleculartherapy.orgEMT changes are a consequence of loss ofVHL gene function and not
related to the use of conventional lentivirus or NIL. But RVN renal
tumors also metastasized rampantly to lungs compared to RC tumors
in immune-deficient mice.15 Hence, we asked whether the intrarenal
tumors of clonal VHL-KO cells will display metastatic behavior in
BALB/c mice similar to RVN tumors. Interestingly, when the
VHL-KO cells were implanted intrarenally, the primary tumor grew
very poorly compared to VHL-WT cells with no increase in lung
metastasis, as observed by FL-based bioluminescence imaging (BLI)
used to track the in vivo growth and metastasis of tumors (Figure 3I).
Likewise, clonally selected RVN1 generated with integration compe-
tent lentiCRISPR also grew poorly in immunodeficient mice (data not
shown). These findings are consistent with the decreased proliferation
rate of the mesenchymal VHL-deleted cells we observed here and
previously.15
Next, we decided to assess the metastatic potential of our VHL-deleted
cells by recreating the mixed cell populations of the original RVN cell
line. Estimating 80% of the RVN cells possessed theVHL gene deletion,
we establish renal tumors with a mixture of VHL-KO and VHL-WT
cells at a ratio of 4:1, referred to herein as the VHL-KO mixed tumor.
Orthotopic renal tumors were established with either VHL-WT cells
only or the 4:1 mixed VHK-KO:VHL-WT cells, totaling 1  106 cells
per tumor. Primary tumors from both groups grew robustly over a
6-week duration (Figure 4A). Remarkably, all BALB/c mice bearing
the VHL-KO mixed tumors (three out of three animals) developed
fulminant lung metastasis, while none of control VHL-WT tumors
developed metastases. The metastatic progression was observed by
BLI, gross pathology, and histopathological analyses (Figures 3I, 4A,
and 4B). H&E stain revealed large primary tumors grew in the kidney
from both VHL-WT cells and the VHL-KO mixed cells (Figure 4C).
Numerous and large lung metastatic lesions developed only in mice
bearingVHL-KOmixed tumors, but not in theVHL-WT tumor group
(Figure 4C). Consistent with findings from our subcutaneous tumors
(Figure 3D), VHL-WT and VHL-KO mixed kidney tumors or their
lung metastatic lesions do not induce a significant infiltration of CD3
cells, confirming a lack of an immune response against tumor cells
generated using the NIL method (Figure 4D). Interestingly, VHL-KO
mixed tumors also exhibited increased vascular density, assessed by
CD31 stain, compared to the VHL-WT tumors (Figure 4E).
Despite multiple attempts, we were unable to establish tumors in syn-
geneic immunocompetent mice with clonally selected lentiCRISPR-
modified cell lines. We surmised that the stably expressed Cas9 could
be promoting the immune-mediated rejection in the mice. Our find-
ings show that the use of NIL vectors can successfully perform the
gene-editing task and can also circumvent this immune-mediated
rejection. This NIL approach enables the successful establishment
of a VHL-gene-deleted metastatic RCC model in immunocompetent
animals.
DISCUSSION
Herein, we describe the use of NIL, also known as the integrase-
deficient lentiviral vector,17 to deliver CRISPR/Cas9 system toMolecuknockout the VHL gene in the murine RENCA RCC cell line. As
reported by Ortinski et al.,17 NIL is comparable to traditional inte-
gration competent lentivirus in regard to vector production capa-
bility as well as efficiency of Cas9-mediated gene knockout. Despite
the widespread use of lentiCRISPR in genetic modification of cell
lines, there is a paucity of reports describing implantable Cas9-
modified immunocompetent murine models. We deduced that
this could be due to an immune reaction against the stably ex-
pressed Cas9 protein, which has been reported.6 However, we are
unaware of previous reports that demonstrate tumor regression or
lack of growth in an immunocompetent host. In this study, we
showed that the NIL CRISPR system that substitutes one plasmid
in the workflow of gene transduction enables the development of
non-integrated clones capable of being implanted into immuno-
competent mice.
Our VHL knockout, immunocompetent RENCA model improves
upon the original RENCA model by making it more clinically appli-
cable in a number of ways. As many as 80%–90% of clinical clear-
cell RCC have disruption of the VHL gene, either through genetic
mutations, deletions, or epigenetic silencing.18 Interestingly, the
VHL-deleted RVN line is much more aggressive and metastatic
than the parental RENCA model.19–21 But the RVN line is a mixed
non-clonal line. Upon further characterization, we found that pure
clone of VHL-deleted lines are slow growing and non-metastatic
in vivo. Furthermore, as we showed here, a mixture of pure clone
of VHL-KO and VHL-WT cells (derived from NIL CRISPR vectors)
are highly metastatic compared to tumors developed from VHL-WT
cells only. These findings indicate that the VHL-KO and VHL-WT
cells are acting in a cooperative manner to produce the heightened
metastatic behavior. We are actively investigating the cross-talk be-
tween these two cell populations and the detailed mechanism of
metastasis. Several important studies have demonstrated a role for
cross-talk between heterogeneous tumor cell populations in the
development of metastases.22,23 In particular, a recent study by Nee-
lakantan et al.23 reported that interactions between EMT and non-
EMT cells induced metastasis in breast cancer models. Our chimeric
VHL-KO and VHL-WT clear cell RCC here will also help to shed
light on the important issue of tumor heterogeneity in cancer
progression.
This study presents a significant contribution to the field via our new,
metastatic clear cell RCC model that can be studied in an immuno-
competent mouse. This model is particularly relevant given the cur-
rent increased interest in immunotherapy. Interleukin-2 treatment
has long been an approved immunotherapy modality for the treat-
ment of RCC, and recent successes with immune checkpoint inhibi-
tors have re-invigorated interest in immunotherapy research for
this cancer.24,25 With the current lack of success using transgenic ap-
proaches to generate a metastatic, VHL-deficient, immunocompetent
RCC model,19–21 our CRISPR-modified immunocompetent model
presented herein is a valuable tool for assessing the immune contribu-
tions to RCCmetastasis and investigating potential immunotherapies
in murine studies.lar Therapy: Methods & Clinical Development Vol. 9 June 2018 207
Figure 4. A VHL-Knockout, Immunocompetent, Metastatic RCC Model
Intrarenal tumors were established in BALB/c mice with 106 VHL-WT cells or a 1:4 ratio of VHL-WT and VHL-KO cells. (A) BLI was used to detect firefly-luciferase-expressing
tumors in vivo. Three representative tumor-bearingmice in each group at the endpoint 6 weeks after tumor implantation were shown. (B) Gross images and unmagnified H&E
stain of harvested organs, including the primary kidney tumor and contralateral normal kidney, as well as lung and heart from both groups, were shown. (C) Higher
magnification H&E stains of primary tumors and lungs were shown. (D) Immunohistochemical stain of CD3 in the primary tumor to identify infiltrating T lymphocytes in both
groups. (E) Immunohistochemistry staining of CD31 depicting the blood vessels within the primary tumor were performed.Whole-section scanning was performed by Applied
Imaging Leica Aperio Versa high-throughput scanning system, and quantification was performed by Definiens’ Tissue Studio at TPCL of UCLA. The angiogenesis was
evaluated by CD31 positivity area within tumor region and denoted by % as shown in the right. (*p < 0.05)
Molecular Therapy: Methods & Clinical Development
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Table 1. Cell Line Information
Cell Line IentiCRISPR Plasmid gRNA Sequence (50–30 Original Cell Line
RC1 Rluc 2 50-CACCGGATGATAACTGGTCCGCAG-30 RENCA
RVN1 mVHL 1 50-CACCGCCCGGTGGTAAGATCGGGT-30 RENCA
RC(NIC1–3) RLuc 2 50-CACCGGATGATAACTGGTCCGCAG-30 RENCA-FL
RVN(NIC1–9) mVHL 1 50-CACCGCCCGGTGGTAAGATCGGGT-30 RENCA-FL
LentiCRISPR plasmids, gRNA sequences, and parental cell lines for the clonal cell lines generated for our studies. Rluc 2, the plasmid containing gRNA sequences targeting renilla
luciferase; mVHL, the plasmid containing gRNA sequences targeting murine VHL; RENCA-FL, the cell line contains sequences encoding firefly luciferase.
www.moleculartherapy.orgMATERIALS AND METHODS
Cell Culture and Generation of Non-integrated Cas9-Modified
Clonal Cell Lines
Cell lines were generated and maintained using techniques as previ-
ously described.15 The NIL was created using packaging plasmid
pCMVDR(int-)8-2 (kind gift from Dr. Noriyuki Kasahara).14 Cells
were transduced as previously described,17 then selected with puro-
mycin (2mg/mL) from 48 to 96 hr following transduction. Cells
were expanded and underwent clonal selection as previously
described.15 Details on the specific gRNA and its target for each clonal
cell line are provided in Table 1. Cas9 expression was assessed by
RT-PCR and western blot using CRISPR/Cas9 monoclonal antibody
(EpiGentek A-9000-050). Cas9 protein served as a positive control
(PNA Bio CP01). Expression of VHL was validated by western blot
as previously described.
Subcutaneous and Orthotopic Tumor Study
All animal experiments were approved by the UCLA IACUC and
conformed to all local and national animal care guidelines and regu-
lations. Female 6- to 8-week-old BALB/c mice (Jackson Laboratory)
were used for tumor implantation. For subcutaneous tumors,
mice were implanted with 1  106 RENCA, RC(NIC1), RC1, or
RENCA-FL cells under the right flank. Tumor measurements were
made by caliper to assess for growth. Mice we sacrificed 20 days
following implantation. Peripheral blood was collected at endpoint
through eye bleeding, and serum was collected for subsequent ELISA
assay. Tumors were processed as previously described.17
For orthotopic intrarenal tumors, mice were placed in the prone po-
sition and an incision was made on the left flank. The left kidney
was partially exteriorized. A Hamilton syringe (28G) was used to
inject either 1  106 RC(NIC1) cells or a mixture of 8  105
RVN(NIC5) cells and 2  105 RC(NIC1) cells in 10 mL of Matrigel
(Corning 354234) diluted with pre-cooled PBS in a 1:1 ratio
under the kidney capsule. Mice were euthanized with isoflurane
inhalation followed with cervical dislocation after 6 weeks. All tu-
mor sectioning and H&E staining was done by the Translational Pa-
thology Core Laboratory (TPCL) at University of California, Los
Angeles.
Western Blot and Immunohistochemistry Staining
Western blotting was performed as previously described.15 After 3%
paraformaldehyde (PFA) fixation overnight and 50% ethanol pres-Molecuervation, tissues were embedded in paraffin wax and cut at 4 mm
thickness. For VHL stain, tumor sections were incubated with
VHL (sc-5575, 1:200, Santa Cruz). Histological images were either
taken by the Nikon Eclipse 90i microscope or scanned by UCLA
TPCL.
Immunohistochemistry staining for CD3 was performed on a Bond
III autostainer (Leica Biosystems, Buffalo Grove, IL) using the Bond
Polymer Refine Detection Kit (DS9800; Leica Biosystems). Antigen
retrieval was performed on the Bond III using Bond Epitope Retrieval
Solution 1 (Citrate; pH 6.0) for 30 min. Slides were incubated at room
temperature with rabbit monoclonal anti-CD3 antibody (ab16669;
Abcam, Cambridge, MA; clone SP7) (1:150) diluted in Bond Primary
Antibody Diluent (AR9352; Leica Biosystems) for 30 min. Slides were
subsequently incubated with the horseradish peroxidase (HRP)-con-
jugated secondary antibody for 10 min. Staining was visualized by
incubating the slides with the chromogen 3,3’-diaminobenzidine
(DAB) for 5 min, and the slides were counterstained with hematoxy-
lin. Finally, slides were dehydrated in graded ethanol and xylene and
coverslipped. Slides were digitized using the Scanscope XT (Aperio
Technologies, Visa, CA).
ELISA
ELISA for expression of Cas9-specific IgG1 was performed as previ-
ously described.6 Accordingly, 96-well Nunc Maxisorp Plates
(Thermo Scientific, cat. #44-2404-21) were coated with SpCas9
protein (PNA Bio, cat. #CP01) at 0.5 mg/well with 1 coating solution
concentrate (KPL, cat. #50-84-00) at 4C. Then on day 2, plates were
washed with 1 wash solution concentrate (KPL, cat. #50-63-00) and
blocked with 1% BSA blocking/Diluent Solution (KPL, cat. #5140-
0006) at 25C for 1 hr. Mouse sera diluted by 1% BSA diluent solution
(KPL, cat. #5140-0006) at the ratio of 1:1,000 were applied to the
coated plate. Mouse monoclonal anti-SpCas9 (Epigentek, cat.
#A-9000-010) were added to plot the standard curve. After rinse,
HRP-labeled goat anti-mouse IgG1 (Santa Cruz, 1:5,000) were
applied at 25C for 1 hr. Then 1 2,2’-azinobis [3-ethylbenzothiazo-
line-6-sulfonic acid]-diammonium salt (ABTS) ELISAHRP Substrate
(KPL, cat. #5120-0032) were added and examined with Synergy HT
microplate reader (BioTek) at 410 nm for further analysis.
Statistics
Data are presented as mean ± SEM. Comparisons between groups
were analyzed by Student’s t test.lar Therapy: Methods & Clinical Development Vol. 9 June 2018 209
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